[Table_Info1] 英科医疗(300677) 医药生物 [Table_Date] 发布时间：2025-07-02 [Table_Title] 证券研究报告 / 公司点评报告 推出限制性股票激励计划，彰显未来发展信心 [Table_Summary] 事件： 公司公告 2025 年限制性股票激励计划，6 月 20 日已向 1090 名激励对 象授予 1324.31 万股限制性股票，约占公告时总股本的 3.94%，授予价 格为 11.30 元/股。公司层面业绩考核目标值为，2026-2029 年公司营业 收入分别不低于 112.60/ 122.80/ 132.80/ 142.80 亿元，或归母净利润（剔 除股份支付费用后）分别不低于 16.80/ 18.80/ 22.80/ 26.80 亿元。 点评： 本次授予股票数量、激励人数远高于上一期，有助于调动高管和核心骨 干人员积极性，并且指引 2027-2029 年收入同比增速分别为 9.1%/ 8.1%/ 7.5%，或净利润增速为 11.9%/ 21.3%/ 17.5%，彰显公司对未来发 展信心。 手套价格逐步企稳，公司在手订单充足。2025 年 1 月以来， ...

证券研究报告：医药生物 | 公司点评报告 发布时间：2025-07-01 股票投资评级 买入 |维持 个股表现 2024-07 2024-09 2024-11 2025-02 2025-04 2025-06 -25% -20% -15% -10% -5% 0% 5% 10% 15% 20% 25% 英科医疗 医药生物 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 23.68 | | --- | --- | | 总股本/流通股本（亿股）6.46 | / 4.69 | | 总市值/流通市值（亿元）153 | / 111 | | 52 周内最高/最低价 | 33.61 / 20.71 | | 资产负债率(%) | 48.9% | | 市盈率 | 10.48 | | 第一大股东 | 刘方毅 | 研究所 公司轮椅品类持续推出新产品。2024 年公司重磅推出了最新产 品 Doly 手动轮椅车、Luxe 电动代步车，这些产品都具备轻便折叠的 优势；以及 STAR 电动轮椅车。未来公司会不断加强在代步车、电动 起身椅、助行器等多个品类产品上的技术研发投入，在康养器械板块 多维发展，打造全面的英科医疗 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Yingke Medical, indicating a low PE ratio compared to the industry average [1][2] - As of July 1, Yingke Medical's closing price was 24.37 yuan, with a PE ratio of 9.97, marking a 60-day low and a total market capitalization of 15.75 billion yuan [1] - The medical device industry has an average PE ratio of 51.70, with Yingke Medical ranking 31st among its peers [1][2] Group 2 - In terms of capital flow, on July 1, Yingke Medical experienced a net inflow of 18.16 million yuan, although it has seen a total outflow of 25.73 million yuan over the past five days [1] - The company's main business involves the research, production, and sales of high-performance personal protective products, including disposable gloves and masks [1] - For Q1 2025, Yingke Medical reported revenue of 2.494 billion yuan, a year-on-year increase of 13.20%, and a net profit of 353 million yuan, reflecting a 48.08% year-on-year growth with a gross margin of 24.16% [1]

蓝帆医疗股份有限公司 公开发行可转换公司债券 三、本报告引用的资料主要由该公司或第三方相关主体提供，联合资信 履行了必要的尽职调查义务，但对引用资料的真实性、准确性和完整性不作 任何保证。联合资信合理采信其他专业机构出具的专业意见，但联合资信不 对专业机构出具的专业意见承担任何责任。 www.lhratings.com 联合〔2025〕5291 号 联合资信评估股份有限公司通过对蓝帆医疗股份有限公司主体 及其相关债券的信用状况进行跟踪分析和评估，确定下调蓝帆医疗 股份有限公司主体长期信用等级为 AA-，下调"蓝帆转债"信用等级 为 AA-，评级展望为稳定。 特此公告 联合资信评估股份有限公司 评级总监： 二〇二五年六月二十七日 跟踪评级报告 | 声 明 一、本报告是联合资信基于评级方法和评级程序得出的截至发表之日的 独立意见陈述，未受任何机构或个人影响。评级结论及相关分析为联合资信 基于相关信息和资料对评级对象所发表的前瞻性观点，而非对评级对象的事 实陈述或鉴证意见。联合资信有充分理由保证所出具的评级报告遵循了真 实、客观、公正的原则。鉴于信用评级工作特性及受客观条件影响，本报告 在资料信息获取、评级方法与模 ...

英科医疗科技股份有限公司的主营业务是高性能高品质的个人防护产品的研发、生产以及销售。公司的 主要产品是一次性丁腈手套、一次性PVC手套、一次性PE手套、隔离服、口罩、电动轮椅车、手动轮 椅车、电动代步车、助步器、电动沙发、医用床边桌、冰袋/热袋、免洗消毒液、暖贴、冷热袋、凉 垫、心电电极片、标签电极。 最新一期业绩显示，2025年一季报，公司实现营业收入24.94亿元，同比13.20%；净利润3.53亿元，同 比48.08%，销售毛利率24.16%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31英科医疗9.4310.160.84148.95亿行业平均 51.0048.824.68108.70亿行业中值37.0337.302.5049.80亿1天益医疗-1801.27-3085.371.9222.95亿2澳华内 镜-688.49345.315.5272.56亿3诺唯赞-425.24-502.942.3391.00亿4爱朋医疗-416.91316.735.0234.21亿5博晖 创新-341.86542.483.6550.16亿6奥精医疗-150.60-220.731.9927.95亿7硕世生物-1 ...

Group 1 - The medical consumables sector experienced a 2.21% increase last week, outperforming the CSI 300 index by 3.3 percentage points [1] - The current PE ratio for the medical consumables sector is 30.61X, with a year-to-date maximum of 52.08X and a minimum of 28.42X [1] - The current PB ratio is 2.21X, with a year-to-date maximum of 2.92X and a minimum of 1.99X [1] Group 2 - Zhonghong Medical announced the establishment of a new overseas glove production line with a total investment of RMB 557 million, expected to take 18 months to complete [2] - Sino Medical's subsidiary received approval for a blood flow-guided mesh stent, marking it as the first of its kind in China with an anti-thrombus coating [2] - Low-value consumable companies are expanding overseas to enhance risk resilience, while high-value consumables are expected to benefit from ongoing domestic procurement reforms [2] Group 3 - The medical consumables industry is recommended to focus on two main lines: performance recovery opportunities post-collection pressure and increased penetration of innovative products [3][4] - Companies with improving performance in orthopedic consumables and those with rich product lines and high innovation in high-value consumables are suggested for attention [4]

Group 1: Financial Performance - Bawang Tea Ji reported a net profit of 677 million yuan for Q1 2025, representing a year-on-year increase of 13.8% [1] - The company achieved a total net revenue of 3.39 billion yuan in Q1 2025, up 35.4% year-on-year, with a total GMV of 8.23 billion yuan, a 38% increase [1] - Sutech Ju Chuang's Q1 revenue was approximately 330 million yuan, with a gross profit of 77.01 million yuan, reflecting a 73.1% year-on-year growth [3] Group 2: Expansion and Strategic Initiatives - Bawang Tea Ji's global store count reached 6,681, with active user numbers hitting 44.9 million in the same quarter [1] - Zhonghong Medical plans to invest 557 million yuan in the first phase of its SEA2 production base, which will include 10 production lines for nitrile gloves [2] - Lemo announced a partnership with NIO to launch the Lemmo Zero smart folding electric bike, designed for compact storage and integration with NIO's vehicle systems [9] Group 3: Market Developments - Hong Kong's Legislative Council passed the Stablecoin Bill, allowing companies like JD to issue stablecoins to enhance cross-border payment capabilities [5] - The Hong Kong Stock Exchange has received significant inquiries following the launch of the "Tech Company Fast Track," indicating a growing interest in IPOs from mainland companies [12][13] - The National Foreign Exchange Administration reported that China's goods and services trade reached 43,706 billion yuan in April 2025, with a year-on-year growth of 6% [14]

Core Viewpoint - The company has approved an investment project to build a glove production line, aiming to enhance operational efficiency and competitiveness [1] Investment Project Details - The company will invest in the SEA2 production base, specifically in the first phase which includes 10 nitrile glove production lines [1] - The total investment for the project is RMB 557 million, with up to RMB 279 million sourced from excess raised funds [1] - The construction period for the project is set at 18 months, with an estimated payback period of approximately 6.01 to 7.76 years, and an expected return on investment rate of 7.59% to 11.33% [1] Strategic Alignment - This project aligns with the company's strategic development plan and is expected to facilitate the expansion of overseas business [1] - The initiative is anticipated to further enhance the company's overall competitive strength in the market [1]

Core Points - The company reported a revenue of 9.523 billion yuan for 2024, representing a year-on-year growth of 37.65%, and a net profit of 1.465 billion yuan, which is an increase of 282.63% compared to the previous year [2][7] - The company achieved a capacity utilization rate of 100% and focused on optimizing market layout to gain more market share, leading to significant performance growth [2][3] - The company is facing an 80% tariff on medical-grade nitrile gloves, a 55% tariff on industrial-grade nitrile gloves, and a 30% tariff on PVC gloves in the U.S. market, which accounts for approximately 30%-35% of its overseas revenue [4][7] Performance Disclosure - For 2024, the company reported a revenue of 9.523 billion yuan, a 37.65% increase year-on-year, and a net profit of 1.465 billion yuan, reflecting a 282.63% growth compared to the previous year [2][7] - The company maintained a capacity utilization rate of 100%, indicating strong operational efficiency [2] Institutional Research - During the performance briefing on May 19, the company attributed its 2024 growth to improved supply-demand dynamics in the disposable glove industry and increased sales prices compared to 2023 [3] - The company is leveraging its production, capital, and sales channel advantages to capture a larger market share [3] Company Announcements - The company has repurchased 2,523,900 shares, accounting for 0.3906% of its total share capital, with a total transaction amount of approximately 53.52 million yuan [5] - The company plans to distribute a total cash dividend of approximately 269.61 million yuan for 2024, which represents 18.40% of the net profit attributable to shareholders [6] - The company is adjusting its 2022 restricted stock incentive plan's performance assessment indicators due to geopolitical complexities and trade friction risks, which will be submitted for shareholder approval [8]

业，精益求精，加大多元化市场布局力度与整合上下游供应链等工 作，2024 年度公司充分发挥了现有生产、资本、销售渠道等方面的 优势，争取占有更多的市场份额。报告期内，公司产能利用率达 100%。因此 2024 年度公司业绩收获了良好增长，经营情况保持行业 领先水平。感谢您的关注！ 2、目前美国对中国一次性手套关税为多少？ 回复：尊敬的投资者您好，目前美国对中国一次性医疗级丁腈 手套关税为 80%，一次性工业级丁腈手套关税为 55%，一次性 PVC 手套关税为 30%。 证券代码：300677 证券简称：英科医疗 英科医疗科技股份有限公司 投资者关系活动记录表 编号：2025-002 | | | | □特定对象调研□分析师会议 | | | --- | --- | --- | --- | --- | | | □媒体采访■业绩说明会 | | | | | 投资者关系活动类别 | □新闻发布会□路演活动 | | | | | | □现场参观 □一对一沟通 | | | | | | □其他 | | | | | 参与单位名称 | 社会公众、投资者等 | | | | | 地点 | 中 国 证 券 报 · 中 证 网 " 路 演 ...